Developing Innovative Oral Drugs for Obesity and Neurodegenerative Diseases
Restoring cellular homeostasis and metabolism
An imbalance in mitochondrial dynamics can disrupt mitochondrial function, leading to abnormal cellular fate, and a range of diseases, including neurodegenerative disorders, metabolic diseases, cardiovascular diseases and cancers.
Our platform of oral small molecules repairs cellular homeostasis resulting in improved cellular energy metabolism, improved clearance of toxic proteins and reversal of metabolically induced cellular aging.
Parkinson’s Disease
AS-006 is a brain penetrant, orally available modifier of mitochondrial metabolism.
Neuropathic Pain
AS-002 is an oral small molecule, repairs mitochondria damage and resolves inflammation.
Alzheimer’s Disease
AS-XXX has demonstrated direct neuroprotective effects, restoration of neural networks.
Statistical Figures
10 years
Obesity reduces life expectancy by up to 10 years
170 Billion
Obesity induced diseases cost $170 billion annually by 2030
4 Trillion
Total economic cost of obesity is forecast at $4 trillion by 2035
200 Billion
Weight loss drugs are expected to sell $200 billion annually by 2030
Our Team
A Strong Combination of Scientific and Business Experience
Ish Khanna, PhD
CEO, CSO, Co-founder
Marcus Malkmus
COO
Kathrin Kortschak
Head of Business Development
Dominic Schiller
Head of IP Strategy